— Know what they know.
Not Investment Advice
Also trades as: C6O.DE (XETRA) · $vol 0M

CLVS NASDAQ

Clovis Oncology, Inc.
1W: -39.0% 1M: -76.7% 3M: -93.0% 1Y: -97.5% 3Y: -99.3% 5Y: -99.9%
$0.08
Last traded 2022-12-20 — delisted
NASDAQ · Healthcare · Biotechnology

Balance Sheet Trends

Total Assets
$473M -21.9% ▼
5Y CAGR: +5.3%
Total Liabilities
$752M -1.7% ▼
5Y CAGR: +15.3%
Shareholders Equity
-$279M -75.6% ▼
Cash & Investments
$143M -40.3% ▼
5Y CAGR: -11.6%
Total Debt
$638M -1.3% ▼
5Y CAGR: +14.0%
Net Debt
$495M +21.7% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2017FY2018FY2019FY2020FY2021
— Assets —
Cash$464M$222M$162M$240M$143M
Short-Term Investments$100M$298M$135M$0$0
Cash & ST Investments$564M$520M$297M$240M$143M
Net Receivables$6M$13M$21M$27M$27M
Inventory$28M$27M$27M$31M$14M
Other Current Assets$30M$12M$23M$13M$14M
Total Current Assets$627M$572M$366M$311M$198M
Property, Plant & Equip.$4M$27M$43M$43M$26M
Goodwill & Intangibles$85M$115M$126M$129M$123M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$20M$150M$134M$123M$126M
Total Non-Current Assets$108M$291M$303M$295M$275M
Total Assets$735M$864M$670M$606M$473M
— Liabilities —
Accounts Payable$15M$29M$32M$27M$27M
Short-Term Debt$0$0$5M$5M$3M
Deferred Revenue$0$847K$4M$907K$0
Other Current Liabilities$66M$97M$95M$153M$94M
Total Current Liabilities$82M$126M$133M$185M$125M
Long-Term Debt$282M$575M$674M$531M$626M
Other Non-Current Liab.$4M$16M$37M$49M$0
Total Non-Current Liabilities$286M$591M$711M$579M$626M
Total Liabilities$368M$717M$844M$764M$752M
— Equity —
Common Stock$51K$53K$55K$104K$129K
Retained Earnings-$1.5B-$1.8B-$2.2B-$2.6B-$2.9B
Accumulated OCI-$42M-$45M-$45M-$44M-$43M
Total Stockholders Equity$368M$146M-$174M-$159M-$279M
Total Liabilities & Equity$735M$864M$670M$606M$473M
— Key Metrics —
Total Debt$382M$577M$685M$647M$638M
Net Debt-$82M$355M$523M$407M$495M
Total Investments$100M$298M$135M$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms